nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Parkinson's disease—Bromocriptine—type 2 diabetes mellitus	0.361	1	CpDpCtD
L-DOPA—L-Phenylalanine—Nateglinide—type 2 diabetes mellitus	0.0954	1	CrCrCtD
L-DOPA—DRD5—Bromocriptine—type 2 diabetes mellitus	0.0511	0.156	CbGbCtD
L-DOPA—DRD4—Bromocriptine—type 2 diabetes mellitus	0.0365	0.111	CbGbCtD
L-DOPA—SLC15A1—Chlorpropamide—type 2 diabetes mellitus	0.0361	0.11	CbGbCtD
L-DOPA—SLC15A1—Tolbutamide—type 2 diabetes mellitus	0.0321	0.0981	CbGbCtD
L-DOPA—SLC15A1—Ramipril—type 2 diabetes mellitus	0.0287	0.0874	CbGbCtD
L-DOPA—SLC15A1—Nateglinide—type 2 diabetes mellitus	0.0273	0.0834	CbGbCtD
L-DOPA—DRD3—Bromocriptine—type 2 diabetes mellitus	0.0271	0.0827	CbGbCtD
L-DOPA—DRD1—Bromocriptine—type 2 diabetes mellitus	0.0261	0.0797	CbGbCtD
L-DOPA—SLC15A1—Glyburide—type 2 diabetes mellitus	0.0185	0.0563	CbGbCtD
L-DOPA—DRD2—Bromocriptine—type 2 diabetes mellitus	0.0159	0.0484	CbGbCtD
L-DOPA—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00834	0.0255	CbGbCtD
L-DOPA—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0077	0.0235	CbGbCtD
L-DOPA—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00632	0.0193	CbGbCtD
L-DOPA—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00606	0.0185	CbGbCtD
L-DOPA—DDC—nerve—type 2 diabetes mellitus	0.00185	0.0704	CbGeAlD
L-DOPA—DRD1—nerve—type 2 diabetes mellitus	0.00136	0.0517	CbGeAlD
L-DOPA—PSIP1—retina—type 2 diabetes mellitus	0.00135	0.0511	CbGeAlD
L-DOPA—PSIP1—nephron tubule—type 2 diabetes mellitus	0.00127	0.0481	CbGeAlD
L-DOPA—PSIP1—cardiovascular system—type 2 diabetes mellitus	0.00114	0.0432	CbGeAlD
L-DOPA—PSIP1—cortex of kidney—type 2 diabetes mellitus	0.00109	0.0412	CbGeAlD
L-DOPA—SLC7A8—islet of Langerhans—type 2 diabetes mellitus	0.00104	0.0394	CbGeAlD
L-DOPA—PSIP1—adipose tissue—type 2 diabetes mellitus	0.001	0.0381	CbGeAlD
L-DOPA—SLC7A8—nephron tubule—type 2 diabetes mellitus	0.000836	0.0317	CbGeAlD
L-DOPA—DRD2—nerve—type 2 diabetes mellitus	0.000805	0.0306	CbGeAlD
L-DOPA—SLC7A5—islet of Langerhans—type 2 diabetes mellitus	0.000804	0.0305	CbGeAlD
L-DOPA—SLC7A8—kidney—type 2 diabetes mellitus	0.000734	0.0279	CbGeAlD
L-DOPA—SLC7A8—pancreas—type 2 diabetes mellitus	0.000729	0.0277	CbGeAlD
L-DOPA—DDC—nephron tubule—type 2 diabetes mellitus	0.000723	0.0275	CbGeAlD
L-DOPA—SLC7A8—cortex of kidney—type 2 diabetes mellitus	0.000715	0.0272	CbGeAlD
L-DOPA—Mimosine—CCL2—type 2 diabetes mellitus	0.000708	0.22	CrCbGaD
L-DOPA—PSIP1—liver—type 2 diabetes mellitus	0.000704	0.0267	CbGeAlD
L-DOPA—SLC7A5—retina—type 2 diabetes mellitus	0.000688	0.0261	CbGeAlD
L-DOPA—SLC7A8—adipose tissue—type 2 diabetes mellitus	0.000662	0.0251	CbGeAlD
L-DOPA—SLC7A5—nephron tubule—type 2 diabetes mellitus	0.000648	0.0246	CbGeAlD
L-DOPA—DDC—kidney—type 2 diabetes mellitus	0.000635	0.0241	CbGeAlD
L-DOPA—DDC—cortex of kidney—type 2 diabetes mellitus	0.000619	0.0235	CbGeAlD
L-DOPA—SLC7A5—cardiovascular system—type 2 diabetes mellitus	0.000582	0.0221	CbGeAlD
L-DOPA—SLC7A5—pancreas—type 2 diabetes mellitus	0.000565	0.0215	CbGeAlD
L-DOPA—SLC7A5—cortex of kidney—type 2 diabetes mellitus	0.000554	0.021	CbGeAlD
L-DOPA—SLC15A1—nephron tubule—type 2 diabetes mellitus	0.000538	0.0204	CbGeAlD
L-DOPA—SLC7A5—adipose tissue—type 2 diabetes mellitus	0.000513	0.0195	CbGeAlD
L-DOPA—SLC16A10—nephron tubule—type 2 diabetes mellitus	0.000496	0.0188	CbGeAlD
L-DOPA—SLC15A1—kidney—type 2 diabetes mellitus	0.000472	0.0179	CbGeAlD
L-DOPA—SLC7A8—liver—type 2 diabetes mellitus	0.000464	0.0176	CbGeAlD
L-DOPA—Masoprocol—IGF1R—type 2 diabetes mellitus	0.000462	0.144	CrCbGaD
L-DOPA—Isoprenaline—PIK3R1—type 2 diabetes mellitus	0.000456	0.142	CrCbGaD
L-DOPA—SLC16A10—cortex of kidney—type 2 diabetes mellitus	0.000424	0.0161	CbGeAlD
L-DOPA—DDC—liver—type 2 diabetes mellitus	0.000402	0.0152	CbGeAlD
L-DOPA—SLC16A10—adipose tissue—type 2 diabetes mellitus	0.000393	0.0149	CbGeAlD
L-DOPA—SLC7A5—liver—type 2 diabetes mellitus	0.00036	0.0137	CbGeAlD
L-DOPA—DRD2—retina—type 2 diabetes mellitus	0.000333	0.0127	CbGeAlD
L-DOPA—SLC15A1—liver—type 2 diabetes mellitus	0.000299	0.0113	CbGeAlD
L-DOPA—SLC16A10—liver—type 2 diabetes mellitus	0.000275	0.0105	CbGeAlD
L-DOPA—Droxidopa—ADRB3—type 2 diabetes mellitus	0.000181	0.0564	CrCbGaD
L-DOPA—CYP2D6—kidney—type 2 diabetes mellitus	0.000166	0.00629	CbGeAlD
L-DOPA—Isoprenaline—ADRB3—type 2 diabetes mellitus	0.000165	0.0513	CrCbGaD
L-DOPA—Norepinephrine—ADRB3—type 2 diabetes mellitus	0.000153	0.0475	CrCbGaD
L-DOPA—Epinephrine—ADRB3—type 2 diabetes mellitus	0.000139	0.0431	CrCbGaD
L-DOPA—Methyldopa—ADRA2A—type 2 diabetes mellitus	0.000132	0.0409	CrCbGaD
L-DOPA—Levonordefrin—ADRA2A—type 2 diabetes mellitus	0.000117	0.0362	CrCbGaD
L-DOPA—Mesalazine—PPARG—type 2 diabetes mellitus	0.000116	0.0361	CrCbGaD
L-DOPA—CYP2D6—liver—type 2 diabetes mellitus	0.000105	0.00398	CbGeAlD
L-DOPA—Droxidopa—ADRA2A—type 2 diabetes mellitus	8.21e-05	0.0255	CrCbGaD
L-DOPA—Norepinephrine—ADRA2A—type 2 diabetes mellitus	6.91e-05	0.0215	CrCbGaD
L-DOPA—Fatigue—Gliclazide—type 2 diabetes mellitus	6.51e-05	0.000579	CcSEcCtD
L-DOPA—Nausea—Glipizide—type 2 diabetes mellitus	6.49e-05	0.000577	CcSEcCtD
L-DOPA—Vomiting—Glimepiride—type 2 diabetes mellitus	6.48e-05	0.000576	CcSEcCtD
L-DOPA—Hypotension—Valsartan—type 2 diabetes mellitus	6.48e-05	0.000576	CcSEcCtD
L-DOPA—Vision blurred—Losartan—type 2 diabetes mellitus	6.48e-05	0.000576	CcSEcCtD
L-DOPA—Vomiting—Sitagliptin—type 2 diabetes mellitus	6.46e-05	0.000575	CcSEcCtD
L-DOPA—Pain—Gliclazide—type 2 diabetes mellitus	6.45e-05	0.000574	CcSEcCtD
L-DOPA—Constipation—Gliclazide—type 2 diabetes mellitus	6.45e-05	0.000574	CcSEcCtD
L-DOPA—Tremor—Losartan—type 2 diabetes mellitus	6.44e-05	0.000573	CcSEcCtD
L-DOPA—Rash—Glimepiride—type 2 diabetes mellitus	6.43e-05	0.000572	CcSEcCtD
L-DOPA—Dermatitis—Glimepiride—type 2 diabetes mellitus	6.42e-05	0.000571	CcSEcCtD
L-DOPA—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	6.42e-05	0.000571	CcSEcCtD
L-DOPA—Rash—Sitagliptin—type 2 diabetes mellitus	6.41e-05	0.00057	CcSEcCtD
L-DOPA—Dermatitis—Sitagliptin—type 2 diabetes mellitus	6.4e-05	0.000569	CcSEcCtD
L-DOPA—Headache—Glimepiride—type 2 diabetes mellitus	6.39e-05	0.000568	CcSEcCtD
L-DOPA—Ill-defined disorder—Losartan—type 2 diabetes mellitus	6.38e-05	0.000567	CcSEcCtD
L-DOPA—Cough—Irbesartan—type 2 diabetes mellitus	6.37e-05	0.000567	CcSEcCtD
L-DOPA—Headache—Sitagliptin—type 2 diabetes mellitus	6.37e-05	0.000566	CcSEcCtD
L-DOPA—Anaemia—Losartan—type 2 diabetes mellitus	6.35e-05	0.000565	CcSEcCtD
L-DOPA—Agitation—Losartan—type 2 diabetes mellitus	6.32e-05	0.000562	CcSEcCtD
L-DOPA—Oedema—Metformin—type 2 diabetes mellitus	6.32e-05	0.000562	CcSEcCtD
L-DOPA—Hypertension—Irbesartan—type 2 diabetes mellitus	6.3e-05	0.000561	CcSEcCtD
L-DOPA—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	6.29e-05	0.00056	CcSEcCtD
L-DOPA—Flushing—Ramipril—type 2 diabetes mellitus	6.28e-05	0.000559	CcSEcCtD
L-DOPA—Angioedema—Losartan—type 2 diabetes mellitus	6.28e-05	0.000559	CcSEcCtD
L-DOPA—Insomnia—Valsartan—type 2 diabetes mellitus	6.27e-05	0.000558	CcSEcCtD
L-DOPA—Epinephrine—ADRA2A—type 2 diabetes mellitus	6.27e-05	0.0195	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS2—type 2 diabetes mellitus	6.25e-05	0.0194	CrCbGaD
L-DOPA—Paraesthesia—Valsartan—type 2 diabetes mellitus	6.23e-05	0.000554	CcSEcCtD
L-DOPA—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	6.22e-05	0.000553	CcSEcCtD
L-DOPA—Chest pain—Irbesartan—type 2 diabetes mellitus	6.22e-05	0.000553	CcSEcCtD
L-DOPA—Shock—Metformin—type 2 diabetes mellitus	6.21e-05	0.000553	CcSEcCtD
L-DOPA—Insomnia—Orlistat—type 2 diabetes mellitus	6.2e-05	0.000551	CcSEcCtD
L-DOPA—Malaise—Losartan—type 2 diabetes mellitus	6.2e-05	0.000551	CcSEcCtD
L-DOPA—Anxiety—Irbesartan—type 2 diabetes mellitus	6.2e-05	0.000551	CcSEcCtD
L-DOPA—Hypersensitivity—Glyburide—type 2 diabetes mellitus	6.19e-05	0.000551	CcSEcCtD
L-DOPA—Thrombocytopenia—Metformin—type 2 diabetes mellitus	6.18e-05	0.00055	CcSEcCtD
L-DOPA—Dyspnoea—Valsartan—type 2 diabetes mellitus	6.18e-05	0.00055	CcSEcCtD
L-DOPA—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	6.17e-05	0.000549	CcSEcCtD
L-DOPA—Somnolence—Valsartan—type 2 diabetes mellitus	6.16e-05	0.000548	CcSEcCtD
L-DOPA—Syncope—Losartan—type 2 diabetes mellitus	6.16e-05	0.000548	CcSEcCtD
L-DOPA—Paraesthesia—Orlistat—type 2 diabetes mellitus	6.15e-05	0.000547	CcSEcCtD
L-DOPA—Leukopenia—Losartan—type 2 diabetes mellitus	6.15e-05	0.000547	CcSEcCtD
L-DOPA—Discomfort—Irbesartan—type 2 diabetes mellitus	6.14e-05	0.000546	CcSEcCtD
L-DOPA—Hyperhidrosis—Metformin—type 2 diabetes mellitus	6.1e-05	0.000543	CcSEcCtD
L-DOPA—Dyspepsia—Valsartan—type 2 diabetes mellitus	6.1e-05	0.000543	CcSEcCtD
L-DOPA—Dizziness—Bromocriptine—type 2 diabetes mellitus	6.08e-05	0.000541	CcSEcCtD
L-DOPA—Dry mouth—Irbesartan—type 2 diabetes mellitus	6.08e-05	0.000541	CcSEcCtD
L-DOPA—Palpitations—Losartan—type 2 diabetes mellitus	6.07e-05	0.00054	CcSEcCtD
L-DOPA—Nausea—Glimepiride—type 2 diabetes mellitus	6.05e-05	0.000539	CcSEcCtD
L-DOPA—Arrhythmia—Ramipril—type 2 diabetes mellitus	6.05e-05	0.000538	CcSEcCtD
L-DOPA—Loss of consciousness—Losartan—type 2 diabetes mellitus	6.04e-05	0.000537	CcSEcCtD
L-DOPA—Nausea—Sitagliptin—type 2 diabetes mellitus	6.04e-05	0.000537	CcSEcCtD
L-DOPA—Dyspepsia—Orlistat—type 2 diabetes mellitus	6.03e-05	0.000537	CcSEcCtD
L-DOPA—Asthenia—Glyburide—type 2 diabetes mellitus	6.03e-05	0.000536	CcSEcCtD
L-DOPA—Decreased appetite—Valsartan—type 2 diabetes mellitus	6.03e-05	0.000536	CcSEcCtD
L-DOPA—Anorexia—Metformin—type 2 diabetes mellitus	6.02e-05	0.000535	CcSEcCtD
L-DOPA—Cough—Losartan—type 2 diabetes mellitus	6e-05	0.000533	CcSEcCtD
L-DOPA—Urticaria—Gliclazide—type 2 diabetes mellitus	6e-05	0.000533	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	5.99e-05	0.000533	CcSEcCtD
L-DOPA—Alopecia—Ramipril—type 2 diabetes mellitus	5.98e-05	0.000532	CcSEcCtD
L-DOPA—Fatigue—Valsartan—type 2 diabetes mellitus	5.98e-05	0.000532	CcSEcCtD
L-DOPA—Abdominal pain—Gliclazide—type 2 diabetes mellitus	5.97e-05	0.000531	CcSEcCtD
L-DOPA—Oedema—Irbesartan—type 2 diabetes mellitus	5.96e-05	0.00053	CcSEcCtD
L-DOPA—Decreased appetite—Orlistat—type 2 diabetes mellitus	5.96e-05	0.00053	CcSEcCtD
L-DOPA—Pruritus—Glyburide—type 2 diabetes mellitus	5.95e-05	0.000529	CcSEcCtD
L-DOPA—Epinephrine—TNF—type 2 diabetes mellitus	5.94e-05	0.0185	CrCbGaD
L-DOPA—Mental disorder—Ramipril—type 2 diabetes mellitus	5.93e-05	0.000528	CcSEcCtD
L-DOPA—Constipation—Valsartan—type 2 diabetes mellitus	5.93e-05	0.000528	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	5.92e-05	0.000526	CcSEcCtD
L-DOPA—Fatigue—Orlistat—type 2 diabetes mellitus	5.91e-05	0.000526	CcSEcCtD
L-DOPA—Hypotension—Metformin—type 2 diabetes mellitus	5.9e-05	0.000525	CcSEcCtD
L-DOPA—Shock—Irbesartan—type 2 diabetes mellitus	5.86e-05	0.000522	CcSEcCtD
L-DOPA—Pain—Orlistat—type 2 diabetes mellitus	5.86e-05	0.000521	CcSEcCtD
L-DOPA—Chest pain—Losartan—type 2 diabetes mellitus	5.85e-05	0.00052	CcSEcCtD
L-DOPA—Vomiting—Bromocriptine—type 2 diabetes mellitus	5.85e-05	0.00052	CcSEcCtD
L-DOPA—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	5.84e-05	0.000519	CcSEcCtD
L-DOPA—Anxiety—Losartan—type 2 diabetes mellitus	5.83e-05	0.000519	CcSEcCtD
L-DOPA—Rash—Bromocriptine—type 2 diabetes mellitus	5.8e-05	0.000516	CcSEcCtD
L-DOPA—Dermatitis—Bromocriptine—type 2 diabetes mellitus	5.79e-05	0.000515	CcSEcCtD
L-DOPA—Tension—Ramipril—type 2 diabetes mellitus	5.78e-05	0.000514	CcSEcCtD
L-DOPA—Discomfort—Losartan—type 2 diabetes mellitus	5.78e-05	0.000514	CcSEcCtD
L-DOPA—Dysgeusia—Ramipril—type 2 diabetes mellitus	5.77e-05	0.000513	CcSEcCtD
L-DOPA—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	5.76e-05	0.000512	CcSEcCtD
L-DOPA—Headache—Bromocriptine—type 2 diabetes mellitus	5.76e-05	0.000512	CcSEcCtD
L-DOPA—Diarrhoea—Glyburide—type 2 diabetes mellitus	5.75e-05	0.000512	CcSEcCtD
L-DOPA—Nervousness—Ramipril—type 2 diabetes mellitus	5.72e-05	0.000509	CcSEcCtD
L-DOPA—Dry mouth—Losartan—type 2 diabetes mellitus	5.72e-05	0.000509	CcSEcCtD
L-DOPA—Anorexia—Irbesartan—type 2 diabetes mellitus	5.68e-05	0.000505	CcSEcCtD
L-DOPA—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	5.67e-05	0.000504	CcSEcCtD
L-DOPA—Paraesthesia—Metformin—type 2 diabetes mellitus	5.67e-05	0.000504	CcSEcCtD
L-DOPA—Muscle spasms—Ramipril—type 2 diabetes mellitus	5.67e-05	0.000504	CcSEcCtD
L-DOPA—Confusional state—Losartan—type 2 diabetes mellitus	5.66e-05	0.000503	CcSEcCtD
L-DOPA—Feeling abnormal—Orlistat—type 2 diabetes mellitus	5.65e-05	0.000502	CcSEcCtD
L-DOPA—Dyspnoea—Metformin—type 2 diabetes mellitus	5.63e-05	0.000501	CcSEcCtD
L-DOPA—Somnolence—Metformin—type 2 diabetes mellitus	5.61e-05	0.000499	CcSEcCtD
L-DOPA—Oedema—Losartan—type 2 diabetes mellitus	5.61e-05	0.000499	CcSEcCtD
L-DOPA—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	5.6e-05	0.000498	CcSEcCtD
L-DOPA—Hypotension—Irbesartan—type 2 diabetes mellitus	5.57e-05	0.000495	CcSEcCtD
L-DOPA—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	5.56e-05	0.000495	CcSEcCtD
L-DOPA—Dyspepsia—Metformin—type 2 diabetes mellitus	5.56e-05	0.000494	CcSEcCtD
L-DOPA—Tremor—Ramipril—type 2 diabetes mellitus	5.52e-05	0.000491	CcSEcCtD
L-DOPA—Shock—Losartan—type 2 diabetes mellitus	5.52e-05	0.000491	CcSEcCtD
L-DOPA—Urticaria—Valsartan—type 2 diabetes mellitus	5.51e-05	0.00049	CcSEcCtD
L-DOPA—Thrombocytopenia—Losartan—type 2 diabetes mellitus	5.49e-05	0.000488	CcSEcCtD
L-DOPA—Decreased appetite—Metformin—type 2 diabetes mellitus	5.49e-05	0.000488	CcSEcCtD
L-DOPA—Abdominal pain—Valsartan—type 2 diabetes mellitus	5.48e-05	0.000488	CcSEcCtD
L-DOPA—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	5.47e-05	0.000486	CcSEcCtD
L-DOPA—Nausea—Bromocriptine—type 2 diabetes mellitus	5.46e-05	0.000486	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	5.45e-05	0.000485	CcSEcCtD
L-DOPA—Fatigue—Metformin—type 2 diabetes mellitus	5.44e-05	0.000484	CcSEcCtD
L-DOPA—Urticaria—Orlistat—type 2 diabetes mellitus	5.44e-05	0.000484	CcSEcCtD
L-DOPA—Hyperhidrosis—Losartan—type 2 diabetes mellitus	5.42e-05	0.000482	CcSEcCtD
L-DOPA—Abdominal pain—Orlistat—type 2 diabetes mellitus	5.42e-05	0.000482	CcSEcCtD
L-DOPA—Asthenia—Gliclazide—type 2 diabetes mellitus	5.42e-05	0.000482	CcSEcCtD
L-DOPA—Agitation—Ramipril—type 2 diabetes mellitus	5.42e-05	0.000482	CcSEcCtD
L-DOPA—Constipation—Metformin—type 2 diabetes mellitus	5.4e-05	0.00048	CcSEcCtD
L-DOPA—Angioedema—Ramipril—type 2 diabetes mellitus	5.38e-05	0.000479	CcSEcCtD
L-DOPA—Paraesthesia—Irbesartan—type 2 diabetes mellitus	5.35e-05	0.000476	CcSEcCtD
L-DOPA—Anorexia—Losartan—type 2 diabetes mellitus	5.35e-05	0.000476	CcSEcCtD
L-DOPA—Vomiting—Glyburide—type 2 diabetes mellitus	5.34e-05	0.000475	CcSEcCtD
L-DOPA—Pruritus—Gliclazide—type 2 diabetes mellitus	5.34e-05	0.000475	CcSEcCtD
L-DOPA—Malaise—Ramipril—type 2 diabetes mellitus	5.31e-05	0.000473	CcSEcCtD
L-DOPA—Dyspnoea—Irbesartan—type 2 diabetes mellitus	5.31e-05	0.000473	CcSEcCtD
L-DOPA—Rash—Glyburide—type 2 diabetes mellitus	5.3e-05	0.000471	CcSEcCtD
L-DOPA—Somnolence—Irbesartan—type 2 diabetes mellitus	5.3e-05	0.000471	CcSEcCtD
L-DOPA—Dermatitis—Glyburide—type 2 diabetes mellitus	5.3e-05	0.000471	CcSEcCtD
L-DOPA—Syncope—Ramipril—type 2 diabetes mellitus	5.28e-05	0.00047	CcSEcCtD
L-DOPA—Leukopenia—Ramipril—type 2 diabetes mellitus	5.27e-05	0.000469	CcSEcCtD
L-DOPA—Headache—Glyburide—type 2 diabetes mellitus	5.27e-05	0.000468	CcSEcCtD
L-DOPA—Dyspepsia—Irbesartan—type 2 diabetes mellitus	5.25e-05	0.000467	CcSEcCtD
L-DOPA—Hypotension—Losartan—type 2 diabetes mellitus	5.24e-05	0.000466	CcSEcCtD
L-DOPA—Palpitations—Ramipril—type 2 diabetes mellitus	5.21e-05	0.000463	CcSEcCtD
L-DOPA—Feeling abnormal—Metformin—type 2 diabetes mellitus	5.2e-05	0.000463	CcSEcCtD
L-DOPA—Decreased appetite—Irbesartan—type 2 diabetes mellitus	5.18e-05	0.000461	CcSEcCtD
L-DOPA—Loss of consciousness—Ramipril—type 2 diabetes mellitus	5.18e-05	0.000461	CcSEcCtD
L-DOPA—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.16e-05	0.000459	CcSEcCtD
L-DOPA—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.16e-05	0.000459	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	5.15e-05	0.000458	CcSEcCtD
L-DOPA—Cough—Ramipril—type 2 diabetes mellitus	5.14e-05	0.000457	CcSEcCtD
L-DOPA—Fatigue—Irbesartan—type 2 diabetes mellitus	5.14e-05	0.000457	CcSEcCtD
L-DOPA—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.11e-05	0.000454	CcSEcCtD
L-DOPA—Convulsion—Ramipril—type 2 diabetes mellitus	5.11e-05	0.000454	CcSEcCtD
L-DOPA—Pain—Irbesartan—type 2 diabetes mellitus	5.1e-05	0.000453	CcSEcCtD
L-DOPA—Constipation—Irbesartan—type 2 diabetes mellitus	5.1e-05	0.000453	CcSEcCtD
L-DOPA—Insomnia—Losartan—type 2 diabetes mellitus	5.07e-05	0.000451	CcSEcCtD
L-DOPA—Hypersensitivity—Orlistat—type 2 diabetes mellitus	5.05e-05	0.000449	CcSEcCtD
L-DOPA—Paraesthesia—Losartan—type 2 diabetes mellitus	5.04e-05	0.000448	CcSEcCtD
L-DOPA—Urticaria—Metformin—type 2 diabetes mellitus	5.02e-05	0.000446	CcSEcCtD
L-DOPA—Chest pain—Ramipril—type 2 diabetes mellitus	5.02e-05	0.000446	CcSEcCtD
L-DOPA—Dyspnoea—Losartan—type 2 diabetes mellitus	5e-05	0.000445	CcSEcCtD
L-DOPA—Anxiety—Ramipril—type 2 diabetes mellitus	5e-05	0.000445	CcSEcCtD
L-DOPA—Nausea—Glyburide—type 2 diabetes mellitus	4.99e-05	0.000444	CcSEcCtD
L-DOPA—Abdominal pain—Metformin—type 2 diabetes mellitus	4.99e-05	0.000444	CcSEcCtD
L-DOPA—Dizziness—Gliclazide—type 2 diabetes mellitus	4.99e-05	0.000444	CcSEcCtD
L-DOPA—Somnolence—Losartan—type 2 diabetes mellitus	4.99e-05	0.000444	CcSEcCtD
L-DOPA—Asthenia—Valsartan—type 2 diabetes mellitus	4.98e-05	0.000443	CcSEcCtD
L-DOPA—Discomfort—Ramipril—type 2 diabetes mellitus	4.96e-05	0.000441	CcSEcCtD
L-DOPA—Dyspepsia—Losartan—type 2 diabetes mellitus	4.94e-05	0.000439	CcSEcCtD
L-DOPA—Asthenia—Orlistat—type 2 diabetes mellitus	4.92e-05	0.000437	CcSEcCtD
L-DOPA—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	4.91e-05	0.000437	CcSEcCtD
L-DOPA—Pruritus—Valsartan—type 2 diabetes mellitus	4.91e-05	0.000436	CcSEcCtD
L-DOPA—Dry mouth—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000436	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—type 2 diabetes mellitus	4.9e-05	0.0152	CrCbGaD
L-DOPA—Decreased appetite—Losartan—type 2 diabetes mellitus	4.88e-05	0.000434	CcSEcCtD
L-DOPA—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	4.87e-05	0.000433	CcSEcCtD
L-DOPA—Confusional state—Ramipril—type 2 diabetes mellitus	4.85e-05	0.000431	CcSEcCtD
L-DOPA—Pruritus—Orlistat—type 2 diabetes mellitus	4.85e-05	0.000431	CcSEcCtD
L-DOPA—Fatigue—Losartan—type 2 diabetes mellitus	4.84e-05	0.00043	CcSEcCtD
L-DOPA—Oedema—Ramipril—type 2 diabetes mellitus	4.81e-05	0.000428	CcSEcCtD
L-DOPA—Norepinephrine—CYP1A2—type 2 diabetes mellitus	4.8e-05	0.0149	CrCbGaD
L-DOPA—Vomiting—Gliclazide—type 2 diabetes mellitus	4.8e-05	0.000427	CcSEcCtD
L-DOPA—Constipation—Losartan—type 2 diabetes mellitus	4.8e-05	0.000427	CcSEcCtD
L-DOPA—Pain—Losartan—type 2 diabetes mellitus	4.8e-05	0.000427	CcSEcCtD
L-DOPA—Rash—Gliclazide—type 2 diabetes mellitus	4.76e-05	0.000423	CcSEcCtD
L-DOPA—Dermatitis—Gliclazide—type 2 diabetes mellitus	4.75e-05	0.000423	CcSEcCtD
L-DOPA—Diarrhoea—Valsartan—type 2 diabetes mellitus	4.74e-05	0.000422	CcSEcCtD
L-DOPA—Urticaria—Irbesartan—type 2 diabetes mellitus	4.73e-05	0.000421	CcSEcCtD
L-DOPA—Shock—Ramipril—type 2 diabetes mellitus	4.73e-05	0.000421	CcSEcCtD
L-DOPA—Headache—Gliclazide—type 2 diabetes mellitus	4.73e-05	0.000421	CcSEcCtD
L-DOPA—Abdominal pain—Irbesartan—type 2 diabetes mellitus	4.71e-05	0.000419	CcSEcCtD
L-DOPA—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	4.71e-05	0.000419	CcSEcCtD
L-DOPA—Diarrhoea—Orlistat—type 2 diabetes mellitus	4.69e-05	0.000417	CcSEcCtD
L-DOPA—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	4.65e-05	0.000414	CcSEcCtD
L-DOPA—Feeling abnormal—Losartan—type 2 diabetes mellitus	4.62e-05	0.000411	CcSEcCtD
L-DOPA—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	4.59e-05	0.000408	CcSEcCtD
L-DOPA—Dizziness—Valsartan—type 2 diabetes mellitus	4.59e-05	0.000408	CcSEcCtD
L-DOPA—Anorexia—Ramipril—type 2 diabetes mellitus	4.58e-05	0.000408	CcSEcCtD
L-DOPA—Dizziness—Orlistat—type 2 diabetes mellitus	4.53e-05	0.000403	CcSEcCtD
L-DOPA—Asthenia—Metformin—type 2 diabetes mellitus	4.53e-05	0.000403	CcSEcCtD
L-DOPA—Hypotension—Ramipril—type 2 diabetes mellitus	4.49e-05	0.0004	CcSEcCtD
L-DOPA—Nausea—Gliclazide—type 2 diabetes mellitus	4.48e-05	0.000399	CcSEcCtD
L-DOPA—Pruritus—Metformin—type 2 diabetes mellitus	4.47e-05	0.000397	CcSEcCtD
L-DOPA—Dopamine—CYP1A2—type 2 diabetes mellitus	4.46e-05	0.0139	CrCbGaD
L-DOPA—Urticaria—Losartan—type 2 diabetes mellitus	4.46e-05	0.000396	CcSEcCtD
L-DOPA—Abdominal pain—Losartan—type 2 diabetes mellitus	4.43e-05	0.000394	CcSEcCtD
L-DOPA—Vomiting—Valsartan—type 2 diabetes mellitus	4.41e-05	0.000392	CcSEcCtD
L-DOPA—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.39e-05	0.000391	CcSEcCtD
L-DOPA—Rash—Valsartan—type 2 diabetes mellitus	4.37e-05	0.000389	CcSEcCtD
L-DOPA—Dermatitis—Valsartan—type 2 diabetes mellitus	4.37e-05	0.000389	CcSEcCtD
L-DOPA—Vomiting—Orlistat—type 2 diabetes mellitus	4.36e-05	0.000388	CcSEcCtD
L-DOPA—Epinephrine—CYP1A2—type 2 diabetes mellitus	4.36e-05	0.0135	CrCbGaD
L-DOPA—Insomnia—Ramipril—type 2 diabetes mellitus	4.35e-05	0.000387	CcSEcCtD
L-DOPA—Headache—Valsartan—type 2 diabetes mellitus	4.34e-05	0.000386	CcSEcCtD
L-DOPA—Diarrhoea—Metformin—type 2 diabetes mellitus	4.32e-05	0.000384	CcSEcCtD
L-DOPA—Rash—Orlistat—type 2 diabetes mellitus	4.32e-05	0.000384	CcSEcCtD
L-DOPA—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.32e-05	0.000384	CcSEcCtD
L-DOPA—Dermatitis—Orlistat—type 2 diabetes mellitus	4.32e-05	0.000384	CcSEcCtD
L-DOPA—Headache—Orlistat—type 2 diabetes mellitus	4.29e-05	0.000382	CcSEcCtD
L-DOPA—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.29e-05	0.000381	CcSEcCtD
L-DOPA—Asthenia—Irbesartan—type 2 diabetes mellitus	4.28e-05	0.00038	CcSEcCtD
L-DOPA—Somnolence—Ramipril—type 2 diabetes mellitus	4.28e-05	0.00038	CcSEcCtD
L-DOPA—Dyspepsia—Ramipril—type 2 diabetes mellitus	4.23e-05	0.000377	CcSEcCtD
L-DOPA—Pruritus—Irbesartan—type 2 diabetes mellitus	4.22e-05	0.000375	CcSEcCtD
L-DOPA—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.18e-05	0.000372	CcSEcCtD
L-DOPA—Dizziness—Metformin—type 2 diabetes mellitus	4.18e-05	0.000371	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.15e-05	0.000369	CcSEcCtD
L-DOPA—Fatigue—Ramipril—type 2 diabetes mellitus	4.15e-05	0.000369	CcSEcCtD
L-DOPA—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.13e-05	0.000368	CcSEcCtD
L-DOPA—Nausea—Valsartan—type 2 diabetes mellitus	4.12e-05	0.000366	CcSEcCtD
L-DOPA—Constipation—Ramipril—type 2 diabetes mellitus	4.11e-05	0.000366	CcSEcCtD
L-DOPA—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.08e-05	0.000363	CcSEcCtD
L-DOPA—Nausea—Orlistat—type 2 diabetes mellitus	4.07e-05	0.000362	CcSEcCtD
L-DOPA—Asthenia—Losartan—type 2 diabetes mellitus	4.02e-05	0.000358	CcSEcCtD
L-DOPA—Vomiting—Metformin—type 2 diabetes mellitus	4.02e-05	0.000357	CcSEcCtD
L-DOPA—Rash—Metformin—type 2 diabetes mellitus	3.98e-05	0.000354	CcSEcCtD
L-DOPA—Dermatitis—Metformin—type 2 diabetes mellitus	3.98e-05	0.000354	CcSEcCtD
L-DOPA—Pruritus—Losartan—type 2 diabetes mellitus	3.97e-05	0.000353	CcSEcCtD
L-DOPA—Feeling abnormal—Ramipril—type 2 diabetes mellitus	3.96e-05	0.000353	CcSEcCtD
L-DOPA—Headache—Metformin—type 2 diabetes mellitus	3.96e-05	0.000352	CcSEcCtD
L-DOPA—Dizziness—Irbesartan—type 2 diabetes mellitus	3.94e-05	0.000351	CcSEcCtD
L-DOPA—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.93e-05	0.00035	CcSEcCtD
L-DOPA—Diarrhoea—Losartan—type 2 diabetes mellitus	3.84e-05	0.000341	CcSEcCtD
L-DOPA—Urticaria—Ramipril—type 2 diabetes mellitus	3.82e-05	0.00034	CcSEcCtD
L-DOPA—Abdominal pain—Ramipril—type 2 diabetes mellitus	3.8e-05	0.000338	CcSEcCtD
L-DOPA—Vomiting—Irbesartan—type 2 diabetes mellitus	3.79e-05	0.000337	CcSEcCtD
L-DOPA—Liothyronine—ALB—type 2 diabetes mellitus	3.76e-05	0.0117	CrCbGaD
L-DOPA—Rash—Irbesartan—type 2 diabetes mellitus	3.76e-05	0.000334	CcSEcCtD
L-DOPA—Dermatitis—Irbesartan—type 2 diabetes mellitus	3.75e-05	0.000334	CcSEcCtD
L-DOPA—Nausea—Metformin—type 2 diabetes mellitus	3.75e-05	0.000334	CcSEcCtD
L-DOPA—Headache—Irbesartan—type 2 diabetes mellitus	3.73e-05	0.000332	CcSEcCtD
L-DOPA—Dizziness—Losartan—type 2 diabetes mellitus	3.71e-05	0.00033	CcSEcCtD
L-DOPA—Vomiting—Losartan—type 2 diabetes mellitus	3.57e-05	0.000317	CcSEcCtD
L-DOPA—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.54e-05	0.000315	CcSEcCtD
L-DOPA—Nausea—Irbesartan—type 2 diabetes mellitus	3.54e-05	0.000315	CcSEcCtD
L-DOPA—Rash—Losartan—type 2 diabetes mellitus	3.54e-05	0.000315	CcSEcCtD
L-DOPA—Dermatitis—Losartan—type 2 diabetes mellitus	3.53e-05	0.000314	CcSEcCtD
L-DOPA—Headache—Losartan—type 2 diabetes mellitus	3.51e-05	0.000313	CcSEcCtD
L-DOPA—Asthenia—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000307	CcSEcCtD
L-DOPA—Pruritus—Ramipril—type 2 diabetes mellitus	3.4e-05	0.000303	CcSEcCtD
L-DOPA—Nausea—Losartan—type 2 diabetes mellitus	3.33e-05	0.000296	CcSEcCtD
L-DOPA—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.29e-05	0.000293	CcSEcCtD
L-DOPA—Dizziness—Ramipril—type 2 diabetes mellitus	3.18e-05	0.000283	CcSEcCtD
L-DOPA—Vomiting—Ramipril—type 2 diabetes mellitus	3.06e-05	0.000272	CcSEcCtD
L-DOPA—Rash—Ramipril—type 2 diabetes mellitus	3.03e-05	0.00027	CcSEcCtD
L-DOPA—Dermatitis—Ramipril—type 2 diabetes mellitus	3.03e-05	0.000269	CcSEcCtD
L-DOPA—Headache—Ramipril—type 2 diabetes mellitus	3.01e-05	0.000268	CcSEcCtD
L-DOPA—Epinephrine—CYP3A4—type 2 diabetes mellitus	2.88e-05	0.00897	CrCbGaD
L-DOPA—Nausea—Ramipril—type 2 diabetes mellitus	2.86e-05	0.000254	CcSEcCtD
L-DOPA—DRD1—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.57e-06	4.82e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	3.56e-06	4.8e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.56e-06	4.8e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—INS—type 2 diabetes mellitus	3.55e-06	4.8e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	3.55e-06	4.78e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CYBA—type 2 diabetes mellitus	3.54e-06	4.78e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.54e-06	4.78e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AVP—type 2 diabetes mellitus	3.53e-06	4.76e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.53e-06	4.76e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.51e-06	4.74e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	3.51e-06	4.73e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.5e-06	4.72e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.49e-06	4.72e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	3.48e-06	4.7e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLAT—type 2 diabetes mellitus	3.47e-06	4.68e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GHRL—type 2 diabetes mellitus	3.47e-06	4.68e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	3.46e-06	4.67e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOB—type 2 diabetes mellitus	3.45e-06	4.66e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.44e-06	4.64e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.44e-06	4.64e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.44e-06	4.64e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.44e-06	4.64e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALDOB—type 2 diabetes mellitus	3.43e-06	4.64e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CALCA—type 2 diabetes mellitus	3.43e-06	4.62e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.42e-06	4.62e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOB—type 2 diabetes mellitus	3.41e-06	4.6e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.4e-06	4.59e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.39e-06	4.58e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.38e-06	4.55e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.35e-06	4.53e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	3.33e-06	4.5e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—C3—type 2 diabetes mellitus	3.3e-06	4.45e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—LPL—type 2 diabetes mellitus	3.3e-06	4.45e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.26e-06	4.41e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—LPL—type 2 diabetes mellitus	3.25e-06	4.39e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.23e-06	4.36e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	3.23e-06	4.36e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	3.21e-06	4.33e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GLP1R—type 2 diabetes mellitus	3.19e-06	4.31e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.19e-06	4.3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	3.17e-06	4.28e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GCG—type 2 diabetes mellitus	3.17e-06	4.28e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.15e-06	4.24e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.14e-06	4.23e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AGT—type 2 diabetes mellitus	3.13e-06	4.23e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	3.12e-06	4.21e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.12e-06	4.21e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.12e-06	4.21e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	3.11e-06	4.2e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.09e-06	4.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.08e-06	4.16e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—LEP—type 2 diabetes mellitus	3.07e-06	4.14e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOE—type 2 diabetes mellitus	3.07e-06	4.14e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.05e-06	4.12e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.04e-06	4.1e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.04e-06	4.1e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR5—type 2 diabetes mellitus	3e-06	4.05e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	2.98e-06	4.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.97e-06	4.01e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—C3—type 2 diabetes mellitus	2.97e-06	4.01e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RELA—type 2 diabetes mellitus	2.93e-06	3.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—C3—type 2 diabetes mellitus	2.93e-06	3.95e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	2.92e-06	3.94e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	2.92e-06	3.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.92e-06	3.94e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.91e-06	3.93e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.9e-06	3.91e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	2.86e-06	3.87e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	2.85e-06	3.84e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	2.85e-06	3.84e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	2.85e-06	3.84e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.83e-06	3.82e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	2.83e-06	3.82e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.82e-06	3.81e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AGT—type 2 diabetes mellitus	2.82e-06	3.81e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.79e-06	3.77e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.79e-06	3.76e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AGT—type 2 diabetes mellitus	2.78e-06	3.76e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	2.78e-06	3.75e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.77e-06	3.74e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—LEP—type 2 diabetes mellitus	2.76e-06	3.73e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOE—type 2 diabetes mellitus	2.76e-06	3.73e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.76e-06	3.72e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	2.75e-06	3.71e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.74e-06	3.7e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.74e-06	3.69e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.73e-06	3.69e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.73e-06	3.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—LEP—type 2 diabetes mellitus	2.73e-06	3.68e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOE—type 2 diabetes mellitus	2.73e-06	3.68e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AVP—type 2 diabetes mellitus	2.7e-06	3.64e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.7e-06	3.64e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.7e-06	3.64e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.69e-06	3.62e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.67e-06	3.61e-05	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.67e-06	3.6e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.65e-06	3.57e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.65e-06	3.57e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.63e-06	3.55e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—INS—type 2 diabetes mellitus	2.62e-06	3.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOB—type 2 diabetes mellitus	2.61e-06	3.52e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.61e-06	3.52e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.6e-06	3.5e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.58e-06	3.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.57e-06	3.47e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.57e-06	3.46e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	2.55e-06	3.44e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	2.55e-06	3.44e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	2.55e-06	3.44e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.54e-06	3.42e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.54e-06	3.42e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.52e-06	3.41e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	2.51e-06	3.38e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.5e-06	3.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LPL—type 2 diabetes mellitus	2.49e-06	3.36e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	2.48e-06	3.35e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.47e-06	3.34e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.47e-06	3.33e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.44e-06	3.29e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.43e-06	3.28e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	2.43e-06	3.28e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.43e-06	3.27e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.41e-06	3.25e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—INS—type 2 diabetes mellitus	2.36e-06	3.19e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.34e-06	3.15e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	2.33e-06	3.15e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—INS—type 2 diabetes mellitus	2.33e-06	3.14e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.32e-06	3.14e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	2.31e-06	3.12e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	2.31e-06	3.12e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SRC—type 2 diabetes mellitus	2.31e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.3e-06	3.1e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.3e-06	3.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.29e-06	3.1e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.29e-06	3.09e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.28e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.28e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.27e-06	3.07e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.25e-06	3.04e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.25e-06	3.04e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	2.25e-06	3.04e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.25e-06	3.03e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.24e-06	3.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—C3—type 2 diabetes mellitus	2.24e-06	3.03e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	2.21e-06	2.99e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	2.21e-06	2.99e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—type 2 diabetes mellitus	2.18e-06	2.94e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.17e-06	2.93e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RELA—type 2 diabetes mellitus	2.17e-06	2.92e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.14e-06	2.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.14e-06	2.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.13e-06	2.88e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGT—type 2 diabetes mellitus	2.13e-06	2.87e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.09e-06	2.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOE—type 2 diabetes mellitus	2.09e-06	2.82e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LEP—type 2 diabetes mellitus	2.09e-06	2.82e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.07e-06	2.79e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.07e-06	2.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.06e-06	2.78e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.06e-06	2.78e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.04e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.04e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.02e-06	2.73e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.97e-06	2.66e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.97e-06	2.66e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.95e-06	2.64e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.95e-06	2.63e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.94e-06	2.62e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RELA—type 2 diabetes mellitus	1.92e-06	2.6e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.91e-06	2.57e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.91e-06	2.57e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.9e-06	2.56e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.87e-06	2.53e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.86e-06	2.51e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.85e-06	2.49e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.83e-06	2.46e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.82e-06	2.45e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.79e-06	2.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—INS—type 2 diabetes mellitus	1.78e-06	2.41e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.77e-06	2.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.77e-06	2.39e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.76e-06	2.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.75e-06	2.37e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.75e-06	2.36e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.75e-06	2.36e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.74e-06	2.34e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.73e-06	2.34e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.72e-06	2.33e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.72e-06	2.33e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.72e-06	2.33e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.72e-06	2.32e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SRC—type 2 diabetes mellitus	1.7e-06	2.3e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.7e-06	2.29e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.69e-06	2.29e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.66e-06	2.24e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.66e-06	2.24e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.65e-06	2.23e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.64e-06	2.22e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.64e-06	2.21e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.64e-06	2.21e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.63e-06	2.2e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.62e-06	2.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.61e-06	2.17e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.59e-06	2.15e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.56e-06	2.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.56e-06	2.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.56e-06	2.11e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.55e-06	2.1e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.53e-06	2.07e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.53e-06	2.07e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.52e-06	2.05e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SRC—type 2 diabetes mellitus	1.51e-06	2.04e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.49e-06	2.01e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.49e-06	2.01e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.49e-06	2.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.47e-06	1.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.47e-06	1.99e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.46e-06	1.97e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.46e-06	1.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.44e-06	1.94e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.43e-06	1.93e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.37e-06	1.85e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.35e-06	1.82e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.34e-06	1.81e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.34e-06	1.81e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.33e-06	1.79e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.32e-06	1.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.32e-06	1.78e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.27e-06	1.71e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.25e-06	1.69e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.24e-06	1.68e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.24e-06	1.67e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.22e-06	1.64e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.16e-06	1.56e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—type 2 diabetes mellitus	1.15e-06	1.55e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.14e-06	1.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.13e-06	1.52e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.09e-06	1.47e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.09e-06	1.47e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.06e-06	1.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.03e-06	1.4e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.03e-06	1.39e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.02e-06	1.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.01e-06	1.37e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	9.98e-07	1.35e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.52e-07	1.28e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.39e-07	1.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	7.79e-07	1.05e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.19e-07	9.7e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	5.01e-07	6.77e-06	CbGpPWpGaD
